Tumor Treating Fields (TTF) Device Market Report 2026

Tumor Treating Fields (TTF) Device Market Overview

• Tumor Treating Fields (TTF) Device market size has reached to $0.65 billion in 2025 • Expected to grow to $1.35 billion in 2030 at a compound annual growth rate (CAGR) of 15.9% • Growth Driver: Increasing Global Cancer Prevalence Fueling The Growth Of The Market Due To Rising Demand For Non-invasive And Targeted Cancer Therapies • Market Trend: Portable TTF Therapy Systems Driving Oncology Device Innovation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tumor Treating Fields (TTF) Device Market?

Tumor treating fields (TTF) devices are non-invasive medical devices that use low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division and slow or stop tumor growth. These devices are primarily used in the treatment of cancers such as glioblastoma and malignant pleural mesothelioma and work by delivering electric fields through transducer arrays placed on the patient’s skin near the tumor site. The main product types of tumor treating fields (TTF) device include portable devices, wearable devices, and accessories and consumables. Portable devices refer to systems that generate low-intensity alternating electric fields to disrupt cancer cell division and inhibit tumor growth. These products are distributed through direct sales, online sales, and distributors and retail pharmacies. The various applications involved are glioblastoma, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and others, and they are used by several end users such as hospitals, specialty cancer centers, ambulatory surgical centers, and home care settings.

What Is The Tumor Treating Fields (TTF) Device Market Growth Forecast?

The tumor treating fields (TTF) device market size is expected to see rapidly grown in the next few years. It will grow to $1.35 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to expansion of indications into additional solid tumors such as Non-Small Cell Lung Cancer and pancreatic cancer, growing preference for home-based oncology treatment delivery, global expansion of reimbursement frameworks for tumor treating fields therapy, increasing adoption of combination treatment approaches with systemic cancer therapies, rising demand for patient-centric and non-invasive cancer care solutions. Major trends in the forecast period include increased reimbursement and payer coverage expansion, shift toward home-based and ambulatory cancer treatment adoption, improved biocompatible transducer arrays reducing skin irritation and improving patient comfort, expansion of clinical adoption across multiple solid tumor indications beyond glioblastoma, growing physician awareness and structured training programs supporting adoption of non-invasive cancer therapies.

Global Tumor Treating Fields (TTF) Device Market Segmentation

1) By Product Type: Portable Devices; Wearable Devices; Accessories And Consumables 2) By Distribution Channel: Direct Sales; Online Sales; Distributors And Retail Pharmacies 3) By Application: Glioblastoma; Non-Small Cell Lung Cancer; Pancreatic Cancer; Ovarian Cancer; Other Cancers 4) By End User: Hospitals; Specialty Cancer Centers; Ambulatory Surgical Centers; Home Care Settings Subsegments: 1) By Portable Devices: Wearable Tumor Treating Fields Devices; Battery-Operated Tumor Treating Fields Devices; Home-Based Portable Tumor Treating Fields Systems; Lightweight Tumor Treating Fields Therapy Devices 2) By Wearable Devices: Head-Mounted Wearable Devices; Body-Worn Wearable Devices; Adhesive Patch Wearable Devices; Portable Battery-Powered Wearable Devices 3) By Accessories And Consumables: Transducer Arrays; Connection Cables; Portable Battery-Powered Wearable Device Accessories; Replacement Consumable Components

What Is The Driver Of The Tumor Treating Fields (TTF) Device Market?

The increasing global cancer prevalence is expected to propel the growth of the tumor treating fields (TTF) device market going forward. Tumor treating fields (TTF) devices refer to non-invasive medical devices that use low-intensity, alternating electric fields to disrupt cancer cell division and inhibit tumor growth in patients with aggressive or hard-to-treat cancers. The prevalence of cancer is increasing due to growing exposure to cancer-causing risk factors worldwide. Tumor treating fields (TTF) devices help address the increasing global cancer burden by providing targeted, non-invasive therapy options that improve treatment outcomes and complement conventional cancer therapies such as chemotherapy and radiation therapy. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022, and the number of new cancer cases is projected to exceed 35 million by 2050, representing a 77% increase from 2022 levels. Therefore, the increasing global cancer prevalence is driving the growth of the tumor treating fields (TTF) device industry.

Key Players In The Global Tumor Treating Fields (TTF) Device Market

Major companies operating in the tumor treating fields (ttf) device market are Novocure Ltd.; Zai Lab

Global Tumor Treating Fields (TTF) Device Market Trends and Insights

Major companies operating in the tumor treating fields (TTF) device market are focusing on developing advanced electric field-based cancer therapy systems to expand treatment applications across multiple cancer types. Electric field-based cancer therapy systems refer to medical devices that use low-intensity alternating electric fields to disrupt cancer cell division and slow or inhibit tumor growth. For instance, in October 2024, Novocure Ltd., a Switzerland-based oncology device company, launched the next-generation Optune Lua system for the treatment of metastatic non-small cell lung cancer (NSCLC). The system delivers Tumor Treating Fields therapy through wearable transducer arrays, enabling continuous and non-invasive treatment while expanding the company’s TTF therapy applications beyond brain cancer indications. It features an upgraded lightweight design with enhanced portability and improved usability, allowing patients to maintain daily activities more comfortably during treatment. Additionally, the system incorporates advanced digital monitoring and treatment-planning capabilities that help optimize therapy delivery, improve adherence tracking, and support personalized treatment management for patients with metastatic non-small cell lung cancer.

What Are Latest Mergers And Acquisitions In The Tumor Treating Fields (TTF) Device Market?

In February 2026, Novocure Ltd., a Switzerland-based oncology device company, partnered with BC Cancer to expand reimbursement coverage for Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma patients in British Columbia, Canada. Through this partnership, Novocure aimed to increase patient access to non-invasive cancer treatment technologies and strengthen the adoption of wearable electric field therapy systems across Canada. According to the company, more than 40,000 patients globally have been treated with TTFields therapy, while Novocure reported approximately $509 million in annual net revenues from its TTFields business. BC Cancer is a Canada-based provincial cancer program specializing in comprehensive cancer treatment, research, and patient care services.

Regional Outlook

North America was the largest region in the tumor treating fields (TTF) device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tumor Treating Fields (TTF) Device Market?

The tumor treating fields (TTF) device market consists of sales of portable electric field generators, transducer arrays, rechargeable battery packs, connection cables, power supply units, carrying accessories, wearable therapy systems, and treatment monitoring software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tumor Treating Fields (TTF) Device Market Report 2026?

The tumor treating fields (ttf) device market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tumor treating fields (ttf) device industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.